Hospital Universitari Parc Tauli

Sabadell, Barcelona 08208

3 studies enrolling now · 8 studies all time

What they study most

Angelman Syndrome, Autosomal Recessive Polycystic Kidney (ARPKD), BRAF V600E-mutant Metastatic Colorectal Cancer, Diffuse Large B-cell Lymphoma (DLBCL), Hip Fractures, Locally Advanced Renal Cell Carcinoma, Locally Advanced Urothelial Cancer, Metastatic Clear-Cell Renal Cell Carcinoma, Metastatic Melanoma, Metastatic Non-small Cell Lung Cancer, Metastatic Urothelial Cancer, Migraine

Studies at this site

• A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD) — Recruiting now
• A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma — Recruiting now
• Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects — Recruiting now
• HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial — Recruiting now
• A Study of the Safety and Tolerability of GTX-102 in Children With Angelman Syndrome — Completed
• Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer — Completed
• Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients — Completed
• A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) — Completed